Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER

(PFE)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
07/16/2019 07/17/2019 07/18/2019 07/19/2019 07/22/2019 Date
42.85(c) 42.74(c) 43.06(c) 42.77(c) 42.855 Last
18 551 648 15 504 260 13 025 669 22 345 912 3 897 195 Volume
+0.23% -0.26% +0.75% -0.67% +0.20% Change
More quotes
Financials (USD)
Sales 2019 53 429 M
EBIT 2019 19 384 M
Net income 2019 12 762 M
Debt 2019 25 930 M
Yield 2019 3,35%
Sales 2020 53 220 M
EBIT 2020 20 208 M
Net income 2020 13 658 M
Debt 2020 25 683 M
Yield 2020 3,51%
P/E ratio 2019 17,9x
P/E ratio 2020 16,7x
EV / Sales2019 4,93x
EV / Sales2020 4,94x
Capitalization 237 B
More Financials
Company
Pfizer the world's leading pharmaceutical group. Net sales break down by family of products as follows: - vaccines, oncology products and consumer medicines (59.8%); - generic medicines (40.2%): for treating cardio-vascular diseases, nervous system disorders, infectious and respiratory diseases,... 
Sector
Pharmaceuticals
Calendar
07/30 | 06:45amEarnings Release
More about the company
Surperformance© ratings of Pfizer
Trading Rating : Investor Rating :
More Ratings
Latest news on PFIZER
10:14aOPKO HEALTH : Announces Appointment of Patricia Sandler as National Sales Direct..
AQ
10:12aCIPLA : InvaGen receives final approval for generic version of Pfizer's Lyrica
AQ
07/18Novartis raises full-year targets, aims to settle U.S. lawsuit
RE
07/18Novartis raises full-year targets, aims to settle U.S. lawsuit
RE
07/17PFIZER : Description Amended tender offer statement by Third Party
PU
07/17PFIZER : Hong Kong Sports and Leisure Expo opens today
AQ
07/16GSK's two-drug HIV Dovato treatment meets main goal in study
RE
07/16TRACKINSIGHT : No limit! S&P500, DJIA and Nasdaq Composite hitting new highs
TI
07/16IAS 2019 ViiV Healthcare showcasing innovation in HIV science
AQ
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
More news
Analyst Recommendations on PFIZER
More recommendations
Sector news : Pharmaceuticals - NEC
11:22aFDA Approves Multiple Applications for Generic Version of Lyrica
DJ
10:43aALLERGAN : Form 8.3 -
DJ
10:18aMERCK AND : Bayer sells Dr. Scholl's footcare brand to Yellow Wood Partners
RE
09:24aBAYER : Sells Dr. Scholl's Brand to Yellow Wood Partners for $585 Million
DJ
06:52aBAYER COULD BENEFIT FROM HOME ADVANT : experts
RE
More sector news : Pharmaceuticals - NEC
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 47,23  $
Last Close Price 42,77  $
Spread / Highest target 28,6%
Spread / Average Target 10,4%
Spread / Lowest Target -4,14%
EPS Revisions
Managers
NameTitle
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-2.02%237 451
JOHNSON & JOHNSON0.98%345 980
ROCHE HOLDING LTD.8.73%230 263
ROCHE HOLDING10.69%230 263
NOVARTIS24.78%216 273
MERCK AND COMPANY6.52%209 550